HRP20130950T1 - Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina - Google Patents

Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina Download PDF

Info

Publication number
HRP20130950T1
HRP20130950T1 HRP20130950AT HRP20130950T HRP20130950T1 HR P20130950 T1 HRP20130950 T1 HR P20130950T1 HR P20130950A T HRP20130950A T HR P20130950AT HR P20130950 T HRP20130950 T HR P20130950T HR P20130950 T1 HRP20130950 T1 HR P20130950T1
Authority
HR
Croatia
Prior art keywords
methyl
phenyl
benzazepin
tetrahydro
trifluoromethyl
Prior art date
Application number
HRP20130950AT
Other languages
English (en)
Croatian (hr)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130950(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20130950T1 publication Critical patent/HRP20130950T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20130950AT 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina HRP20130950T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
HRP20130950T1 true HRP20130950T1 (hr) 2013-11-22

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130950AT HRP20130950T1 (hr) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina

Country Status (37)

Country Link
US (2) US8329688B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
AU2014213125B2 (en) 2013-01-31 2016-06-02 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
CR20110669A (es) 2012-03-16
CA2764425C (en) 2015-01-06
IL216655A (en) 2015-02-26
SI2448933T1 (sl) 2013-11-29
CO6480934A2 (es) 2012-07-16
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
TN2011000638A1 (en) 2013-05-24
DK2448933T3 (da) 2013-10-07
AU2010266537B2 (en) 2013-04-18
UA109409C2 (ru) 2015-08-25
ES2435293T3 (es) 2013-12-18
TW201113275A (en) 2011-04-16
KR20120027426A (ko) 2012-03-21
BRPI1011931A2 (pt) 2016-04-19
PT2448933E (pt) 2013-10-29
MA33385B1 (fr) 2012-06-01
PL2448933T3 (pl) 2014-01-31
GT201100321A (es) 2012-11-15
IL216655A0 (en) 2012-02-29
DOP2011000405A (es) 2012-01-15
AR077208A1 (es) 2011-08-10
JP5689875B2 (ja) 2015-03-25
CN102639528A (zh) 2012-08-15
EP2448933B1 (en) 2013-08-28
MY157121A (en) 2016-05-13
KR101404893B1 (ko) 2014-06-20
NZ596820A (en) 2013-07-26
JO2867B1 (en) 2015-03-15
CN102639528B (zh) 2014-07-16
US20100331309A1 (en) 2010-12-30
WO2011002696A1 (en) 2011-01-06
ZA201108707B (en) 2013-05-29
US8299060B2 (en) 2012-10-30
US8329688B2 (en) 2012-12-11
JP2012532106A (ja) 2012-12-13
ECSP11011551A (es) 2012-01-31
EA020600B1 (ru) 2014-12-30
US20120058990A1 (en) 2012-03-08
CA2764425A1 (en) 2011-01-06
CL2011003263A1 (es) 2012-07-27
EP2448933A1 (en) 2012-05-09
SG177413A1 (en) 2012-02-28
TWI450896B (zh) 2014-09-01
PE20120538A1 (es) 2012-05-09
EA201270099A1 (ru) 2012-05-30
AU2010266537A1 (en) 2012-02-02
MX2011014024A (es) 2012-04-20

Similar Documents

Publication Publication Date Title
JP2012532106A5 (enExample)
ME02655B (me) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
ES2674174T3 (es) Antagonista de LPA1 policíclico y usos del mismo
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
HRP20241789T1 (hr) Čvrsti oblici belumosudila i soli belumosudila
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
ME02892B (me) Hemijska jedinjenja
JP2017504576A5 (enExample)
NZ594641A (en) Pyrazole derivatives used as ccr4 receptor antagonists
RU2008141373A (ru) Соль алискирена и серной кислоты
HRP20230813T1 (hr) Upadacitinib solni spoj i postupak njegove pripreme
ES2655644T3 (es) Sales cristalinas de asenapina
NO20073755L (no) Ibandronatpolymorf B
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
RU2002113750A (ru) Производные пиррола в качестве ингибиторов фосфодиэстеразы VII
JP2009521414A5 (enExample)
HRP20251339T1 (hr) Postupak proizvodnje i međuprodukti pirolo[2,3-d]pirimidinskog spoja i njegova upotreba
RU2015108042A (ru) Способ получения пеметрекседа и его лизиновой соли
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
RU2013137753A (ru) Твердые формы ингибитора гиразы (r)-1-этил-3-[5-[2-(1-гидрокси-1-метилэтил)пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил]мочевины
JP2011529942A5 (enExample)
ES2572652T3 (es) Nuevas formas de un compuesto multicíclico
HRP20161186T1 (hr) Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama
HRP20180865T1 (hr) Kristalni oblik abakavira koji uglavnom ne sadrži otapalo
NZ700221A (en) Ralfinamide methanesulfonate salts